Jing-Ming Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing-Ming Jia has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- An-Hua Wang
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
35 shared publications An-Hua Wang
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China
12 shared publications- Gaosheng Hu
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China
11 shared publications Gao-Sheng Hu
Teaching and Research Department of Chinese Materia Medica Resources, College of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China
10 shared publicationsXiao-Xu Gao
Teaching and Research Department of Chinese Materia Medica Resources, College of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China
10 shared publicationsGuo-Qing Long
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People’s Republic of China
8 shared publications
Latest Publications
- 18 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22427-22459
Brain Penetration Optimization and Anti-neuroinflammation Evaluation of Potent 6-Methyl-7-azaindol-3-yl-quinazoline DYRK1A Inhibitors for Alzheimer’s Disease
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) to regulate microglia-mediated neuroinflammation represents a promising therapeutic strategy for Alzheimer’s disease (AD). To address the limited brain penetration of our earlier lead ZJCK-6-46, an intramolecular cyclization strategy was employed to mask the HBD ability of the P-gp efflux-prone amino and hydroxyl groups in the (S)-2-amino-2-phenylethanol moiety, facilitating comprehensive optimization of physicochemical properties. This effort yielded a more promising candidate, ZJCK-6-72, which maintained the overall kinase selectivity profile despite a 13.5-fold DYRK1A potency reduction and exhibited marked anti-neuroinflammatory activity and lower microglial cytotoxicity. Notably, ZJCK-6-72 showed significantly reduced P-gp efflux liability, and its improved oral absorption and brain penetration synergistically enhanced brain exposure in vivo, which translated into robust efficacy in both LPS-induced and 5×FAD transgenic mouse models. This work provides valuable insights for advancing DYRK1A-targeted AD therapies and establishes a viable paradigm for optimizing brain penetration in CNS drug discovery.
- 18 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (19) , 22427-22459
Brain Penetration Optimization and Anti-neuroinflammation Evaluation of Potent 6-Methyl-7-azaindol-3-yl-quinazoline DYRK1A Inhibitors for Alzheimer’s Disease
Targeting dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) to regulate microglia-mediated neuroinflammation represents a promising therapeutic strategy for Alzheimer’s disease (AD). To address the limited brain penetration of our earlier lead ZJCK-6-46, an intramolecular cyclization strategy was employed to mask the HBD ability of the P-gp efflux-prone amino and hydroxyl groups in the (S)-2-amino-2-phenylethanol moiety, facilitating comprehensive optimization of physicochemical properties. This effort yielded a more promising candidate, ZJCK-6-72, which maintained the overall kinase selectivity profile despite a 13.5-fold DYRK1A potency reduction and exhibited marked anti-neuroinflammatory activity and lower microglial cytotoxicity. Notably, ZJCK-6-72 showed significantly reduced P-gp efflux liability, and its improved oral absorption and brain penetration synergistically enhanced brain exposure in vivo, which translated into robust efficacy in both LPS-induced and 5×FAD transgenic mouse models. This work provides valuable insights for advancing DYRK1A-targeted AD therapies and establishes a viable paradigm for optimizing brain penetration in CNS drug discovery.
- 14 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158577
Lonicera trichosantha alleviates LPS-induced endometritis in mice by modulating the gut microbiota and host metabolism
- 14 July 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158577
Lonicera trichosantha alleviates LPS-induced endometritis in mice by modulating the gut microbiota and host metabolism
- 28 March 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 311, 118804
Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity
- 28 March 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 311, 118804
Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity
- 11 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 7338-7363
Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a highly aggressive subtype that lacks effective targeted therapies and exhibits strong dependence on CDK9-driven transcription. Here, we report a structure-based drug design strategy exploiting CDK9-specific conformations to discover a novel series of potent inhibitors. This approach yielded HS34, a coumarin-based CDK9 inhibitor with low-nanomolar potency and exceptional selectivity. In cellular assays, HS34 displayed potent antiproliferative activity against TNBC cells, outperforming the reference inhibitor KB-0742. Mechanistically, HS34 suppresses RNAP II Ser2 phosphorylation, leading to the downregulation of short-lived survival and oncogenic proteins such as Mcl-1 and c-Myc, and consequently inducing apoptosis and blocking EMT-associated invasion. Furthermore, HS34 exhibits favorable DMPK properties, including high oral bioavailability and metabolic stability, which align with the significant antitumor efficacy observed in an orally treated xenograft model. Collectively, these findings establish HS34 as a selective CDK9 inhibitor and demonstrate that exploiting target-specific conformational features offers an effective strategy for kinase selectivity.
- 11 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 7338-7363
Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a highly aggressive subtype that lacks effective targeted therapies and exhibits strong dependence on CDK9-driven transcription. Here, we report a structure-based drug design strategy exploiting CDK9-specific conformations to discover a novel series of potent inhibitors. This approach yielded HS34, a coumarin-based CDK9 inhibitor with low-nanomolar potency and exceptional selectivity. In cellular assays, HS34 displayed potent antiproliferative activity against TNBC cells, outperforming the reference inhibitor KB-0742. Mechanistically, HS34 suppresses RNAP II Ser2 phosphorylation, leading to the downregulation of short-lived survival and oncogenic proteins such as Mcl-1 and c-Myc, and consequently inducing apoptosis and blocking EMT-associated invasion. Furthermore, HS34 exhibits favorable DMPK properties, including high oral bioavailability and metabolic stability, which align with the significant antitumor efficacy observed in an orally treated xenograft model. Collectively, these findings establish HS34 as a selective CDK9 inhibitor and demonstrate that exploiting target-specific conformational features offers an effective strategy for kinase selectivity.
- 14 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121167
Exploring the mechanism of dihydromyricetin in alleviating psoriasis based on metabolomics, network pharmacology and experimental validation
- 14 January 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 360, 121167
Exploring the mechanism of dihydromyricetin in alleviating psoriasis based on metabolomics, network pharmacology and experimental validation
- 18 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability
CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural product library identified kushenmin K, a flavonoid with modest CDK inhibitory and antiproliferative activities. A strategy combining scaffold hopping with structure-guided design yielded HS-36, a novel oxazolylflavone derivative, which potently inhibited both CDK4 (IC50 = 18.9 nM) and CDK9 (IC50 = 4.2 nM). This dual activity effectively blocked cell cycle progression and triggered apoptosis by downregulating key downstream effectors, translating into potent antiproliferative activity. Notably, it maintained this potent activity even in CDK4/6 inhibitor-resistant cell models. Furthermore, HS-36 possessed an excellent pharmacokinetic profile, including good oral bioavailability (F = 41.8%), which enabled solid and well-tolerated in vivo antitumor efficacy (TGI = 68.8%) in a MV-4-11 xenograft model. This work not only presents HS-36 as a promising lead compound but also validates our rational approach to optimizing natural product scaffolds.
- 18 December 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability
CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural product library identified kushenmin K, a flavonoid with modest CDK inhibitory and antiproliferative activities. A strategy combining scaffold hopping with structure-guided design yielded HS-36, a novel oxazolylflavone derivative, which potently inhibited both CDK4 (IC50 = 18.9 nM) and CDK9 (IC50 = 4.2 nM). This dual activity effectively blocked cell cycle progression and triggered apoptosis by downregulating key downstream effectors, translating into potent antiproliferative activity. Notably, it maintained this potent activity even in CDK4/6 inhibitor-resistant cell models. Furthermore, HS-36 possessed an excellent pharmacokinetic profile, including good oral bioavailability (F = 41.8%), which enabled solid and well-tolerated in vivo antitumor efficacy (TGI = 68.8%) in a MV-4-11 xenograft model. This work not only presents HS-36 as a promising lead compound but also validates our rational approach to optimizing natural product scaffolds.
- 23 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109134
Polycyclic Polyprenylated Acylphloroglucinols from Hypericum Hookerianum with their immunosuppressive activities
- 23 October 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109134
Polycyclic Polyprenylated Acylphloroglucinols from Hypericum Hookerianum with their immunosuppressive activities
- 15 July 2025
- Published by Elsevier in Fitoterapia
- Vol. 185, 106731
Evaluation of natural prenylflavonoids from Sophora flavescens root bark and their antibacterial activity
- 15 July 2025
- Published by Elsevier in Fitoterapia
- Vol. 185, 106731
Evaluation of natural prenylflavonoids from Sophora flavescens root bark and their antibacterial activity